/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Based in Cambridge, Massachusetts, Biogen Inc. (BIIB) discovers, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Valued at a market cap of $30 billion, the company is also developing products for the treatment of various other diseases, including Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and movement disorders.
Shares of this biotechnology company have significantly underperformed the broader market over the past 52 weeks. BIIB has declined 21.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.5%. In 2024, shares of MSI are down 20.4%, compared to SPX’s 17.7% gain on a YTD basis.
